Emil Lou, Professor with Tenure at University of Minnesota, shared a post on LinkedIn:
“Some reflections here and there on what was presented earlier this month at GI26, the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium:
The return of targeting the tumor microenvironment (for real this time!), in pancreatic cancer? Interim analysis from the Phase II ACCENT trial was presented, incorporating addition of an inhibitor of focal adhesion kinase (FAK) to a standard-of-care chemotherapy backbone (in this case, gemcitabine with nab-paclitaxel). Here is what the investigators did and what they reported:
ACCENT Trial — Narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel as first-line treatment for patients with metastatic pancreatic cancer: Phase 2a results.
Patient Population:
- Patients with metastatic pancreatic cancer receiving first-line therapy.
Treatment Arms: - Narmafotinib + Gemcitabine + nab-Paclitaxel (Gem/Abraxane).
- Historical/reference comparison: Gem/Abraxane alone (benchmark from prior studies).
Key Outcomes:
- Median Progression-Free Survival (PFS): ~7.7 months vs ~5.5 months historically with standard chemo.
- Overall Response Rate (ORR): 35% (42% including unconfirmed responses); compares favorably with ~23% ORR in prior Gem/Abraxane trials.
- Safety: Narmafotinib combination was well tolerated, with adverse events similar to standard chemo alone.
Note that this was an interim analysis from a phase 2 study; overall survival (OS) data were not yet reported at ASCO GI.”
More posts featuring Emil Lou.